The PD-1/PD-L1 pathway can modulate NK-cell activation (19, 83) and can be targeted by immunotherapies that block the PD-1/PD-L1 interaction to enhance NK-cell activation in the context of cancer (18, 28, 29, 31, 38–41). Here, CD274 is linked to cancer.